NASDAQ:KRYS - Krystal Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $24.76 -0.13 (-0.52 %) (As of 12/14/2018 04:00 PM ET)Previous Close$24.76Today's Range$23.5510 - $25.3152-Week Range$8.03 - $28.75Volume48,411 shsAverage Volume47,145 shsMarket Capitalization$359.14 millionP/E Ratio-16.73Dividend YieldN/ABeta-0.66 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania. Receive KRYS News and Ratings via Email Sign-up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS Previous Symbol CUSIPN/A Webwww.krystalbio.com Phone412-586-5830 Debt Debt-to-Equity RatioN/A Current Ratio27.65 Quick Ratio27.65 Price-To-Earnings Trailing P/E Ratio-16.73 Forward P/E Ratio-26.06 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book5.13 Profitability EPS (Most Recent Fiscal Year)($1.48) Net Income$-7,920,000.00 Net MarginsN/A Return on Equity-17.92% Return on Assets-17.56% Miscellaneous Employees12 Outstanding Shares14,430,000Market Cap$359.14 million OptionableNot Optionable Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." How were Krystal Biotech's earnings last quarter? Krystal Biotech Inc (NASDAQ:KRYS) announced its earnings results on Monday, November, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). View Krystal Biotech's Earnings History. When is Krystal Biotech's next earnings date? Krystal Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Krystal Biotech. What price target have analysts set for KRYS? 6 analysts have issued 12-month price objectives for Krystal Biotech's shares. Their predictions range from $32.00 to $38.00. On average, they expect Krystal Biotech's share price to reach $35.00 in the next year. This suggests a possible upside of 41.4% from the stock's current price. View Analyst Price Targets for Krystal Biotech. What is the consensus analysts' recommendation for Krystal Biotech? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech. What are Wall Street analysts saying about Krystal Biotech stock? Here are some recent quotes from research analysts about Krystal Biotech stock: 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (12/11/2018) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating though are lowering our price target to $32 from $35.50. The driver to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count off of October 2018 equity raise; and (3) adjusting our applied P/E multiple from 14.5x to 17.0x, which is our standard multiple in our coverage universe. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (11/5/2018) 3. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and increasing our price target to $35/share from $28/share on Krystal Biotech. This morning, Krystal announced and held a conference call to discuss interim results from two patients in the ongoing Phase 1/2 study (GEM) of KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). The trial met all primary efficacy endpoints for the two patients and showed substantial improvements in time to wound closure, in our view. Importantly, KB103 was well tolerated with no serious adverse events or product- related adverse events reported. Krystal remains on track to complete the study in 1H19." (10/15/2018) Has Krystal Biotech been receiving favorable news coverage? News stories about KRYS stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. Who are some of Krystal Biotech's key competitors? Some companies that are related to Krystal Biotech include Editas Medicine (EDIT), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Autolus Therapeutics (AUTL), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), DBV TECHNOLOGIE/S (DBVT), Solid Biosciences (SLDB), Cellectis (CLLS) and Acorda Therapeutics (ACOR). Who are Krystal Biotech's key executives? Krystal Biotech's management team includes the folowing people: Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 53)Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)Ms. Pooja Agarwal, VP of Product Devel. (Age 39)Mr. Antony A. Riley, Chief Financial Officer (Age 51) When did Krystal Biotech IPO? (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.48%), Vanguard Group Inc (1.20%), Vanguard Group Inc. (1.20%), Baker BROS. Advisors LP (0.79%), S Squared Technology LLC (0.37%) and Renaissance Technologies LLC (0.35%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech. Which major investors are selling Krystal Biotech stock? KRYS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Baker BROS. Advisors LP. View Insider Buying and Selling for Krystal Biotech. Which major investors are buying Krystal Biotech stock? KRYS stock was bought by a variety of institutional investors in the last quarter, including S Squared Technology LLC, Renaissance Technologies LLC, P.A.W. Capital Corp, Vanguard Group Inc, Vanguard Group Inc., JPMorgan Chase & Co. and Acadian Asset Management LLC. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech. How do I buy shares of Krystal Biotech? Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $24.76. How big of a company is Krystal Biotech? Krystal Biotech has a market capitalization of $359.14 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe. What is Krystal Biotech's official website? The official website for Krystal Biotech is http://www.krystalbio.com. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830. MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 124 (Vote Outperform)Underperform Votes: 143 (Vote Underperform)Total Votes: 267MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: How are institutional investors different from individual investors?